Long-term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)

Enrico Smeraldi, Roberto Cavallaro, Vera Folnegović-Šmalc, Leszek Bidzan, Mehmet Emin Ceylan, Andreas Schreiner

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The objective of this study was to report the long-term remission results from the ConstaTRE relapse prevention trial, in which clinically stable adults with schizophrenia or schizoaffective disorder treated with oral risperidone, olanzapine, or oral conventional antipsychotics were randomized to risperidone long-acting injectable (RLAI) or oral quetiapine, dosed according to package-insert recommendations. In the ConstaTRE trial, efficacy and tolerability were recorded for up to 24 months. This post hoc analysis presents remission data, defined, according to the Schizophrenia Working Group criteria, as achieving and maintaining eight core symptoms of schizophrenia that are mild or less over 6 months. Additional secondary outcome measures are also presented. A total of 710 patients were randomized to RLAI (n = 355) or quetiapine (n = 355). Mean mode ± standard deviation (SD) drug doses were RLAI 33 ± 10 mg every 2 weeks and quetiapine 413 ± 159 mg daily. Full remission was achieved by 51.1% of patients with RLAI and 39.3% with quetiapine (p = 0.003). Mean ± SD of full remission durations were not significantly different with RLAI (540 ± 181 days) and quetiapine (508 ± 188 days). Overall tolerability was similar between treatment groups. Among stable patients with schizophrenia or schizoaffective disorder, remission was more likely after switching to RLAI than quetiapine.

Original languageEnglish
Pages (from-to)191-199
Number of pages9
JournalTherapeutic Advances in Psychopharmacology
Volume3
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

Risperidone
Secondary Prevention
Psychotic Disorders
Schizophrenia
Injections
olanzapine
Product Labeling
Quetiapine Fumarate
Antipsychotic Agents
Outcome Assessment (Health Care)
Pharmaceutical Preparations

Keywords

  • antipsychotics
  • long-acting injectable risperidone
  • quetiapine
  • remission
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Psychology (miscellaneous)

Cite this

Long-term remission in schizophrenia and schizoaffective disorder : Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). / Smeraldi, Enrico; Cavallaro, Roberto; Folnegović-Šmalc, Vera; Bidzan, Leszek; Emin Ceylan, Mehmet; Schreiner, Andreas.

In: Therapeutic Advances in Psychopharmacology, Vol. 3, No. 4, 2013, p. 191-199.

Research output: Contribution to journalArticle

Smeraldi, Enrico ; Cavallaro, Roberto ; Folnegović-Šmalc, Vera ; Bidzan, Leszek ; Emin Ceylan, Mehmet ; Schreiner, Andreas. / Long-term remission in schizophrenia and schizoaffective disorder : Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). In: Therapeutic Advances in Psychopharmacology. 2013 ; Vol. 3, No. 4. pp. 191-199.
@article{c67ca46dfacf43a18c36954adc3de5c4,
title = "Long-term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)",
abstract = "The objective of this study was to report the long-term remission results from the ConstaTRE relapse prevention trial, in which clinically stable adults with schizophrenia or schizoaffective disorder treated with oral risperidone, olanzapine, or oral conventional antipsychotics were randomized to risperidone long-acting injectable (RLAI) or oral quetiapine, dosed according to package-insert recommendations. In the ConstaTRE trial, efficacy and tolerability were recorded for up to 24 months. This post hoc analysis presents remission data, defined, according to the Schizophrenia Working Group criteria, as achieving and maintaining eight core symptoms of schizophrenia that are mild or less over 6 months. Additional secondary outcome measures are also presented. A total of 710 patients were randomized to RLAI (n = 355) or quetiapine (n = 355). Mean mode ± standard deviation (SD) drug doses were RLAI 33 ± 10 mg every 2 weeks and quetiapine 413 ± 159 mg daily. Full remission was achieved by 51.1{\%} of patients with RLAI and 39.3{\%} with quetiapine (p = 0.003). Mean ± SD of full remission durations were not significantly different with RLAI (540 ± 181 days) and quetiapine (508 ± 188 days). Overall tolerability was similar between treatment groups. Among stable patients with schizophrenia or schizoaffective disorder, remission was more likely after switching to RLAI than quetiapine.",
keywords = "antipsychotics, long-acting injectable risperidone, quetiapine, remission, schizophrenia",
author = "Enrico Smeraldi and Roberto Cavallaro and Vera Folnegović-Šmalc and Leszek Bidzan and {Emin Ceylan}, Mehmet and Andreas Schreiner",
year = "2013",
doi = "10.1177/2045125313479127",
language = "English",
volume = "3",
pages = "191--199",
journal = "Therapeutic Advances in Psychopharmacology",
issn = "2045-1253",
publisher = "Sage Publications",
number = "4",

}

TY - JOUR

T1 - Long-term remission in schizophrenia and schizoaffective disorder

T2 - Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)

AU - Smeraldi, Enrico

AU - Cavallaro, Roberto

AU - Folnegović-Šmalc, Vera

AU - Bidzan, Leszek

AU - Emin Ceylan, Mehmet

AU - Schreiner, Andreas

PY - 2013

Y1 - 2013

N2 - The objective of this study was to report the long-term remission results from the ConstaTRE relapse prevention trial, in which clinically stable adults with schizophrenia or schizoaffective disorder treated with oral risperidone, olanzapine, or oral conventional antipsychotics were randomized to risperidone long-acting injectable (RLAI) or oral quetiapine, dosed according to package-insert recommendations. In the ConstaTRE trial, efficacy and tolerability were recorded for up to 24 months. This post hoc analysis presents remission data, defined, according to the Schizophrenia Working Group criteria, as achieving and maintaining eight core symptoms of schizophrenia that are mild or less over 6 months. Additional secondary outcome measures are also presented. A total of 710 patients were randomized to RLAI (n = 355) or quetiapine (n = 355). Mean mode ± standard deviation (SD) drug doses were RLAI 33 ± 10 mg every 2 weeks and quetiapine 413 ± 159 mg daily. Full remission was achieved by 51.1% of patients with RLAI and 39.3% with quetiapine (p = 0.003). Mean ± SD of full remission durations were not significantly different with RLAI (540 ± 181 days) and quetiapine (508 ± 188 days). Overall tolerability was similar between treatment groups. Among stable patients with schizophrenia or schizoaffective disorder, remission was more likely after switching to RLAI than quetiapine.

AB - The objective of this study was to report the long-term remission results from the ConstaTRE relapse prevention trial, in which clinically stable adults with schizophrenia or schizoaffective disorder treated with oral risperidone, olanzapine, or oral conventional antipsychotics were randomized to risperidone long-acting injectable (RLAI) or oral quetiapine, dosed according to package-insert recommendations. In the ConstaTRE trial, efficacy and tolerability were recorded for up to 24 months. This post hoc analysis presents remission data, defined, according to the Schizophrenia Working Group criteria, as achieving and maintaining eight core symptoms of schizophrenia that are mild or less over 6 months. Additional secondary outcome measures are also presented. A total of 710 patients were randomized to RLAI (n = 355) or quetiapine (n = 355). Mean mode ± standard deviation (SD) drug doses were RLAI 33 ± 10 mg every 2 weeks and quetiapine 413 ± 159 mg daily. Full remission was achieved by 51.1% of patients with RLAI and 39.3% with quetiapine (p = 0.003). Mean ± SD of full remission durations were not significantly different with RLAI (540 ± 181 days) and quetiapine (508 ± 188 days). Overall tolerability was similar between treatment groups. Among stable patients with schizophrenia or schizoaffective disorder, remission was more likely after switching to RLAI than quetiapine.

KW - antipsychotics

KW - long-acting injectable risperidone

KW - quetiapine

KW - remission

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84997901782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997901782&partnerID=8YFLogxK

U2 - 10.1177/2045125313479127

DO - 10.1177/2045125313479127

M3 - Article

AN - SCOPUS:84997901782

VL - 3

SP - 191

EP - 199

JO - Therapeutic Advances in Psychopharmacology

JF - Therapeutic Advances in Psychopharmacology

SN - 2045-1253

IS - 4

ER -